COLLEGIUM PHARMACEUTICAL, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.3 USD | -1.08% |
|
+5.59% | +8.06% |
| May. 13 | Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program | MT |
| May. 10 | Needham Downgrades Collegium Pharmaceutical to Hold From Buy | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 583M | Sales 2025 * | 597M | Capitalization | 1.1B |
|---|---|---|---|---|---|
| Net income 2024 * | 121M | Net income 2025 * | 148M | EV / Sales 2024 * | 2.14 x |
| Net Debt 2024 * | 146M | Net cash position 2025 * | 194M | EV / Sales 2025 * | 1.52 x |
| P/E ratio 2024 * |
11.1
x | P/E ratio 2025 * |
9.01
x | Employees | 197 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Collegium Pharmaceutical, Inc.
More recommendations
More press releases
| 1 day | -1.22% | ||
| 1 week | +5.59% | ||
| Current month | -9.94% | ||
| 1 month | -6.18% | ||
| 3 months | +3.68% | ||
| 6 months | +32.35% | ||
| Current year | +8.06% |
1 week
31.37
34.81
1 month
30.4238.60
Current year
30.4240.95
1 year
20.8340.95
3 years
14.0440.95
5 years
10.0140.95
10 years
7.3740.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 01-12-31 | |
Joseph Ciaffoni
CEO | Chief Executive Officer | 53 | 17-05-30 |
Colleen Tupper
DFI | Director of Finance/CFO | 48 | 21-05-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Garen Bohlin
BRD | Director/Board Member | 76 | 14-12-31 |
Gino Santini
BRD | Director/Board Member | 66 | 12-07-23 |
John Freund
BRD | Director/Board Member | 70 | 14-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 28 M€ | -0.39% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 33.21 | -1.37% | 16 130 |
| 24-05-16 | 33.67 | -0.91% | 378,763 |
| 24-05-15 | 33.98 | +2.07% | 1,168,230 |
| 24-05-14 | 33.29 | +3.55% | 732,658 |
| 24-05-13 | 32.15 | +2.06% | 884,500 |
Delayed Quote Nasdaq, May 17, 2024 at 09:41 am EDT
More quotes
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
33.67
USD
Average target price
40
USD
Spread / Average Target
+18.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.06% | 1.1B | |
| +31.78% | 694B | |
| +29.54% | 593B | |
| -1.89% | 371B | |
| +19.11% | 331B | |
| +6.16% | 290B | |
| +14.11% | 239B | |
| -3.48% | 209B | |
| +9.87% | 209B | |
| +8.05% | 169B |
- Stock Market
- Equities
- COLL Stock